Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034892 · ClinicalTrials.gov registry record · Phase 3
CAFE Comparison of Atypicals in First Episode of Psychosis
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00034892: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00034892 is a Phase 3 study that has completed, run by AstraZeneca. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00034892, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day) in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder who are experiencing their first psychotic episode.
Interventions
- DRUG Olanzapine, risperidone
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-03 |
| Est. Completion | 2005-03 |
| Phase | Phase 3 |
What the finished NCT00034892 record still lists
NCT00034892 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Olanzapine, risperidone is the first listed.
NCT00034892 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00034892 about?
NCT00034892 is a clinical study titled "CAFE Comparison of Atypicals in First Episode of Psychosis". The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day) in patients with schizophrenia, schizophreniform disorder, or schizoaff...
What is the current status of trial NCT00034892?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-03. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00034892?
The interventions under investigation include: Olanzapine, risperidone (DRUG).
Who is sponsoring clinical trial NCT00034892?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia